# US Patient Blood Management Market

> United States Patient Blood Management Market Research Report By Product (Instruments, Accessories, Reagents and Kits, Software) By End-User (Blood Banks, Hospitals, Diagnostic Clinics, Pathology Labs) By Component (Whole Blood, Plasma) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.32%
- **2024:** $ 2,110 Million
- **2025:** $ 2,243.35 Million
- **2035:** $ 4,140 Million
- **Key Players:** Terumo Corporation (JP), Fresenius SE & Co. KGaA (DE), Haemonetics Corporation (US), Grifols S.A. (ES), Baxter International Inc. (US), Cerus Corporation (US), Blood Centers of America (US), Octapharma AG (CH)

**Report ID:** MRFR/HC/17946-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-patient-blood-management-market-19493

---

## Market Summary

## US Patient Blood Management Market Highlighted Trends & Dynamics

The demand for Patient Blood Management (PBM) in the US is on the rise as healthcare professionals and patients become more aware of the benefits of a comprehensive approach to managing blood use. PBM focuses on optimizing the use of blood products to improve patient outcomes, reduce transfusion-related complications, and enhance overall healthcare efficiency.

Along with the increasing amount of surgical operations in the US there is also an increased need in the feasible blood management strategies. Preoperative optimization and other PBM practice as mentioned such as the judicious use of blood transfusion during procedures can minimize the amount of blood lost in surgeries, thus reducing such a need for transfusions and they also help surgical wounds to heal better and faster.

PBM serves to be pivotal in palliating and treating anemia in health care centers. Though strategies aimed at the prevention of anaemia before surgical operations can only partially cutback the need for blood transfusions, it will considerably improve patient outcomes and better utilization of health care resources.

The patient-centred care is driving the demand for PBM. CRC considers the need to personalize or rather tailor individual blood management strategies to patient needs, taking into account age, health status, and medical history.

PBM reduces unnecessary blood transfusions and associated complications, contributing to efficient healthcare practices. This same strategy goes with the global healthcare industry workings to enhance cost efficiency in the delivery of patent care.

Advancements and advancements in the field of blood analysis and diagnostics undoubtedly have significant turn to the development and fuelling of the PBM market. Modern testing techniques allow for better identification of high-risk patients susceptible to transfusion; early action can be taken by health care workers in managing blood and therefore reducing transfusional use.

In the US, regulatory support and empirical guidelines for blood management practices are the impetuses behind the PBM implementation. The incorporation of PBM protocols in degree in the standard practices of health care institutions is increasing due to regulations against enhancing the overall patient care.

The cooperation or collaborative efforts among the stakeholders in healthcare industry such as blood banks,hospitals and pharmaceutical companies has laid on the ground all the necessary soil towards the implementation of PBM initiatives. Collaborative research, education and adoption of best standards towards patient blood management are the harbingers of a uniform strategy.

PBM education initiatives targeting healthcare practitioners are crucial to get widespread acceptance. Programs and workshops aimed at informing health providers on the fundamentals and advantages of PBM prepare them to put these approaches into their working clinical protocols.

The development and integration of specialized software solutions for patient blood management enhance the efficiency of PBM practices. These solutions aid healthcare providers in tracking and managing blood utilization, ensuring adherence to protocols, and facilitating data-driven decision-making for improved patient outcomes.

## Market Drivers

### Increasing Demand for Blood Products

The rising demand for blood products in the healthcare sector is a crucial driver for the patient blood-management market. As the population ages and the prevalence of chronic diseases increases, the need for blood transfusions and related products is expected to grow. In the US, the American Red Cross reports that every 2 seconds, someone needs blood, highlighting the ongoing necessity for blood management solutions. This demand is projected to increase by approximately 5% annually, prompting healthcare facilities to adopt more efficient blood management practices. Consequently, hospitals and clinics are investing in advanced blood management systems to ensure the availability and safety of blood products, thereby driving growth in the patient blood-management market.

### Technological Integration in Healthcare

The integration of advanced technologies in healthcare is transforming the patient blood-management market. Innovations such as electronic health records (EHRs), artificial intelligence (AI), and data analytics are enhancing blood management processes. For instance, AI-driven algorithms can predict blood demand more accurately, reducing waste and ensuring optimal inventory levels. The market for blood management software is expected to grow by over 10% annually, driven by the need for efficient data management and real-time tracking of blood products. This technological evolution not only streamlines operations but also improves patient outcomes, making it a significant driver for the patient blood-management market.

### Regulatory and Accreditation Requirements

Regulatory and accreditation requirements play a pivotal role in shaping the patient blood-management market. Organizations such as the Food and Drug Administration (FDA) and the American Association of Blood Banks (AABB) set stringent standards for blood collection, storage, and transfusion practices. Compliance with these regulations is essential for healthcare facilities, driving them to invest in robust blood management systems. The need for accreditation by bodies like the Joint Commission further emphasizes the importance of adhering to best practices in blood management. As facilities strive to meet these requirements, the patient blood-management market is expected to expand, reflecting the ongoing commitment to quality and safety in blood transfusion practices.

### Focus on Patient Safety and Quality of Care

Patient safety remains a top priority in healthcare, significantly influencing the patient blood-management market. The emphasis on reducing transfusion-related complications and improving patient outcomes has led to the implementation of stringent protocols and guidelines. According to the Joint Commission, hospitals are increasingly adopting evidence-based practices to enhance blood safety, which may reduce transfusion reactions by up to 30%. This focus on quality care encourages healthcare providers to invest in comprehensive blood management systems that monitor and optimize blood usage. As a result, the patient blood-management market is likely to experience growth as institutions prioritize patient safety and strive to meet regulatory standards.

### Rising Awareness of Blood Conservation Strategies

There is a growing awareness of blood conservation strategies among healthcare providers, which is positively impacting the patient blood-management market. Techniques such as preoperative autologous blood donation and intraoperative blood salvage are gaining traction as they minimize the need for allogeneic blood transfusions. Studies indicate that implementing these strategies can reduce transfusion rates by up to 40%, thereby enhancing patient safety and reducing costs. As hospitals and surgical centers increasingly adopt these practices, the demand for blood management solutions that support conservation efforts is likely to rise, further propelling the patient blood-management market.

## Future Outlook

The [Patient Blood Management Market](https://www.marketresearchfuture.com/reports/patient-blood-management-market-8798) is projected to grow at 6.32% CAGR from 2025 to 2035, driven by technological advancements, regulatory support, and increasing demand for efficient blood management solutions.

**New opportunities:**

- Development of AI-driven blood inventory management systems.
- 
- Expansion of telehealth services for remote patient monitoring.
- Implementation of mobile blood collection units in underserved areas.

By 2035, the market is expected to achieve robust growth, driven by innovation and strategic initiatives.

## Segment Insights

### By Product: Instruments (Largest) vs. Software (Fastest-Growing)

In the US patient blood-management market, the Instruments segment holds the largest share, driven by the increasing demand for advanced blood processing technologies. Accessories and Reagents and Kits follow, capturing significant portions of the market as hospitals and laboratories invest in complete blood management solutions to improve patient outcomes. Software is rapidly gaining traction, particularly in data management and tracking blood usage, as healthcare providers seek to optimize their blood supply chains.

Growth trends in this segment are largely fueled by technological advancements and an increasing focus on patient safety. The surge in surgeries and procedures requiring blood transfusions has heightened the need for efficient blood management systems. Additionally, the move towards automation and digital solutions is propelling Software to become the fastest-growing segment, with providers keen on utilizing technology to enhance operational efficiency and compliance with healthcare regulations.

Instruments (Dominant) vs. Software (Emerging)

The Instruments segment is characterized by a wide array of devices designed for blood collection, processing, and storage, making it the dominant force in the market. Hospitals rely heavily on these instruments for their efficiency and reliability, which leads to continuous innovations aimed at improving performance and patient safety. On the other hand, Software is an emerging segment, focusing on providing digital solutions that streamline blood management processes. It encompasses applications for inventory management, data analysis, and reporting, providing healthcare organizations with valuable insights. As technology evolves, Software's role is becoming increasingly integral, positioning it as a key player in future developments within the US patient blood-management market.

### By Component: Plasma (Largest) vs. Whole Blood (Fastest-Growing)

In the US patient blood-management market, Plasma holds a significant market share, driven by its essential role in various medical treatments and transfusions. Whole Blood, while crucial, accounts for a smaller portion of the market yet shows promising growth in recent years, reflecting the evolving needs of healthcare providers and patients alike.

The growth trends within this segment are influenced by increasing surgical procedures and trauma cases, which elevate the demand for blood components. Innovations in storage and transportation methods for blood products further streamline availability, propelling the usage of Whole Blood. Additionally, the rising awareness and advancements in blood management practices contribute to the robust expansion of both Plasma and Whole Blood products, catering to a dynamic healthcare environment.

Plasma (Dominant) vs. Whole Blood (Emerging)

Plasma is the dominant component in the US patient blood-management market, recognized for its critical efficacy in treating a range of medical conditions including clotting disorders and burn treatments. Its composition, rich in proteins and antibodies, makes it indispensable in therapeutic applications. Conversely, Whole Blood is emerging rapidly, driven by its utility in transfusion practices and surgical procedures. As healthcare providers adapt to new blood management technologies and protocols, Whole Blood is gaining traction due to its comprehensive profile that offers essential elements of red blood cells, white blood cells, and platelets. The evolving landscape of patient care is set to enhance the role of both Plasma and Whole Blood in future medical practices.

### By End-User: Blood Banks (Largest) vs. Hospitals (Fastest-Growing)

In the US patient blood-management market, Blood Banks dominate the end-user segment, holding the largest share due to their critical role in the collection, testing, and distribution of blood products. Hospitals also form a significant part of this market, utilizing blood management strategies to enhance patient care and safety, contributing to their substantial presence in the sector. Meanwhile, Diagnostic Clinics and Pathology Labs are comparatively smaller players, focusing on specialized blood tests and analyses, which further diversifies the market landscape.

Growth in this segment is driven by increasing surgical procedures and a rising prevalence of blood-related disorders, making efficient blood management solutions essential. Blood Banks are continuously innovating to improve storage and processing methods, while Hospitals are rapidly adopting advanced technologies to enhance their blood management systems. This dynamic is creating a competitive atmosphere, with emerging players in the Diagnostic Clinics and Pathology Labs looking to carve out larger market shares through specialized services and improved patient outcomes.

Blood Banks (Dominant) vs. Hospitals (Emerging)

Blood Banks serve as the backbone of the US patient blood-management market, characterized by their extensive operational networks and technological advancements in blood harvesting and preservation techniques. Their dominance is rooted in their ability to provide critical blood products and services needed by hospitals and clinics. On the other hand, Hospitals are emerging as key players within this landscape, increasingly recognizing the need for integrated blood management systems to ensure optimized blood usage and patient outcomes. These institutions are embracing innovative solutions and automated systems to streamline workflows, reduce wastage, and enhance patient safety, effectively positioning themselves as vital components in the evolving market. The interplay between these segments highlights a crucial symbiosis in ensuring a responsive and efficient blood management ecosystem.

## Competitive Benchmarking

The patient blood-management market is characterized by a dynamic competitive landscape, driven by increasing demand for efficient blood management solutions and advancements in technology. Key players such as Haemonetics Corporation (US), Terumo Corporation (JP), and Baxter International Inc. (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Haemonetics Corporation (US) focuses on developing advanced blood management systems, while Terumo Corporation (JP) emphasizes regional expansion and product diversification. Baxter International Inc. (US) is actively pursuing digital transformation initiatives to optimize operational efficiency, collectively shaping a competitive environment that prioritizes technological advancement and customer-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of products and services, fostering competition that drives innovation and quality improvements across the sector.
In October Haemonetics Corporation (US) announced a strategic partnership with a leading healthcare technology firm to integrate AI-driven analytics into its blood management systems. This move is likely to enhance the precision of blood utilization and improve patient outcomes, reflecting a broader trend towards data-driven decision-making in healthcare. The integration of AI could potentially streamline operations and reduce costs, positioning Haemonetics as a leader in the market.
In September Terumo Corporation (JP) launched a new line of blood collection devices designed to improve safety and efficiency in transfusion practices. This product introduction not only underscores Terumo's commitment to innovation but also addresses growing concerns regarding blood safety and patient care. The launch is expected to strengthen Terumo's competitive edge in the US market, appealing to healthcare providers seeking reliable and advanced solutions.
In August Baxter International Inc. (US) expanded its digital health platform to include remote monitoring capabilities for blood management. This strategic enhancement aligns with the increasing demand for telehealth solutions and reflects Baxter's focus on integrating technology into patient care. By offering remote monitoring, Baxter aims to improve patient engagement and outcomes, thereby solidifying its position in the evolving landscape of patient blood management.
As of November current competitive trends indicate a strong emphasis on digitalization, sustainability, and AI integration within the patient blood-management market. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological innovation, supply chain reliability, and enhanced patient outcomes. This shift suggests that companies prioritizing R&D and strategic partnerships will be better positioned to thrive in an increasingly complex market.

## Report Scope

| MARKET SIZE 2024 | 2110.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2243.35(USD Million) |
| MARKET SIZE 2035 | 4140.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.32% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Terumo Corporation (JP), Fresenius SE & Co. KGaA (DE), Haemonetics Corporation (US), Grifols S.A. (ES), Baxter International Inc. (US), Cerus Corporation (US), Blood Centers of America (US), Octapharma AG (CH) |
| Segments Covered | Product, Component, End-User |
| Key Market Opportunities | Integration of advanced data analytics to optimize blood utilization and enhance patient outcomes. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in patient blood-management solutions across healthcare facilities. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US patient blood-management market?**
A: The market valuation was $2110.0 Million in 2024.

**Q: What is the projected market size for the US patient blood-management market by 2035?**
A: The market is projected to reach $4140.0 Million by 2035.

**Q: What is the expected CAGR for the US patient blood-management market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.32% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the US patient blood-management market?**
A: Key players include Terumo Corporation, Fresenius SE & Co. KGaA, Haemonetics Corporation, Grifols S.A., Baxter International Inc., Cerus Corporation, Blood Centers of America, and Octapharma AG.

**Q: What are the main product segments in the US patient blood-management market?**
A: Main product segments include Instruments, Accessories, Reagents and Kits, and Software.

**Q: How did the Instruments segment perform in 2024?**
A: The Instruments segment was valued at $800.0 Million in 2024 and is expected to reach $1600.0 Million by 2035.

**Q: What is the valuation of the Plasma component in the US patient blood-management market?**
A: The Plasma component was valued at $1110.0 Million in 2024 and is projected to grow to $2140.0 Million by 2035.

**Q: Which end-user segment had the highest valuation in 2024?**
A: The Hospitals segment had the highest valuation at $1055.0 Million in 2024.

**Q: What is the projected growth for the Blood Banks segment by 2035?**
A: The Blood Banks segment is projected to grow from $423.0 Million in 2024 to $846.0 Million by 2035.

**Q: How does the performance of the Diagnostic Clinics segment compare to other end-user segments?**
A: The Diagnostic Clinics segment was valued at $423.0 Million in 2024, similar to the Blood Banks segment, indicating a balanced demand across these end-users.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-patient-blood-management-market-19493*